Advertisement

Prevention of allergic asthma through Der p 2 peptide vaccination

  • Author Footnotes
    ∗ These authors contributed equally to this work.
    Gregory Bouchaud
    Footnotes
    ∗ These authors contributed equally to this work.
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France

    INRA, UR1268 BIA, Nantes, France
    Search for articles by this author
  • Author Footnotes
    ∗ These authors contributed equally to this work.
    Faouzi Braza
    Footnotes
    ∗ These authors contributed equally to this work.
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • Julie Chesné
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • David Lair
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • Kuan-Wei Chen
    Affiliations
    Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria
    Search for articles by this author
  • Camille Rolland-Debord
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • Dorian Hassoun
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • Tiphaine Roussey-Bihouée
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • Marie-Aude Cheminant
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France
    Search for articles by this author
  • Sophie Brouard
    Affiliations
    Université de Nantes, Nantes, France

    Institut National de la Santé Et de la Recherche Médicale INSERM U1064, Nantes, France

    Institut de Transplantation Urologie Néphrologie du Centre Hospitalier Universitaire Hôtel Dieu, Nantes, France
    Search for articles by this author
  • Marie Bodinier
    Affiliations
    INRA, UR1268 BIA, Nantes, France
    Search for articles by this author
  • Susanne Vrtala
    Affiliations
    Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria
    Search for articles by this author
  • Antoine Magnan
    Affiliations
    INSERM, UMR1087, l'institut du thorax, Nantes, France

    CNRS, UMR 6291, Nantes, France

    Université de Nantes, Nantes, France

    DHU2020 médecine personnalisée des maladies chroniques, Nantes, France

    CHU de Nantes, l'institut du thorax, Service de Pneumologie, Nantes, France
    Search for articles by this author
  • Author Footnotes
    ∗ These authors contributed equally to this work.
Published:February 11, 2015DOI:https://doi.org/10.1016/j.jaci.2014.12.1938
      House dust mites (HDMs) are a major source of allergens that affect more than 50% of allergic patients.
      • Bousquet P.J.
      • Chinn S.
      • Janson C.
      • Kogevinas M.
      • Burney P.
      • Jarvis D.
      • et al.
      Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I.
      • Meyer C.H.
      • Bond J.F.
      • Chen M.S.
      • Kasaian M.T.
      Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, Dermatophagoides pteronyssinus.
      • van der Zee J.S.
      • van Swieten P.
      • Jansen H.M.
      • Aalberse R.C.
      Skin tests and histamine release with P1-depleted Dermatophagoides pteronyssinus body extracts and purified P1.
      The Dermatophagoides pteronyssinus allergen, Der p 2, is one of the most representative HDM allergens and is recognized by more than 90% of HDM-allergic patients.
      • Bousquet P.J.
      • Chinn S.
      • Janson C.
      • Kogevinas M.
      • Burney P.
      • Jarvis D.
      • et al.
      Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I.
      • Meyer C.H.
      • Bond J.F.
      • Chen M.S.
      • Kasaian M.T.
      Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, Dermatophagoides pteronyssinus.
      • van der Zee J.S.
      • van Swieten P.
      • Jansen H.M.
      • Aalberse R.C.
      Skin tests and histamine release with P1-depleted Dermatophagoides pteronyssinus body extracts and purified P1.
      Continuous exposure to this allergen leads to the development of asthma, a pathology characterized by bronchoconstriction and airway inflammation. Genetic engineering led to the development of new therapeutic recombinant hypoallergenic derivatives with lower IgE and T-cell reactivity.
      • Valenta R.
      • Ferreira F.
      • Focke-Tejkl M.
      • Linhart B.
      • Niederberger V.
      • Swoboda I.
      • et al.
      From allergen genes to allergy vaccines.
      Two recombinant hypoallergenic peptides derived from Der p 2 were recently described to exhibit less in vivo allergenicity than the Der p 2 allergen while preserving immunogenicity.
      • Chen K.W.
      • Blatt K.
      • Thomas W.R.
      • Swoboda I.
      • Valent P.
      • Valenta R.
      • et al.
      Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy.
      • Chen K.W.
      • Focke-Tejkl M.
      • Blatt K.
      • Kneidinger M.
      • Gieras A.
      • Dall'Antonia F.
      • et al.
      Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients.
      Thus, hypoallergenic peptides may represent candidates for specific immunotherapy, especially in HDM-allergic asthma.
      To read this article in full you will need to make a payment

      References

        • Bousquet P.J.
        • Chinn S.
        • Janson C.
        • Kogevinas M.
        • Burney P.
        • Jarvis D.
        • et al.
        Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I.
        Allergy. 2007; 62: 301-309
        • Meyer C.H.
        • Bond J.F.
        • Chen M.S.
        • Kasaian M.T.
        Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, Dermatophagoides pteronyssinus.
        Clin Exp Allergy. 1994; 24: 1041-1048
        • van der Zee J.S.
        • van Swieten P.
        • Jansen H.M.
        • Aalberse R.C.
        Skin tests and histamine release with P1-depleted Dermatophagoides pteronyssinus body extracts and purified P1.
        J Allergy Clin Immunol. 1988; 81: 884-896
        • Valenta R.
        • Ferreira F.
        • Focke-Tejkl M.
        • Linhart B.
        • Niederberger V.
        • Swoboda I.
        • et al.
        From allergen genes to allergy vaccines.
        Annu Rev Immunol. 2010; 28: 211-241
        • Chen K.W.
        • Blatt K.
        • Thomas W.R.
        • Swoboda I.
        • Valent P.
        • Valenta R.
        • et al.
        Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy.
        J Allergy Clin Immunol. 2012; 130: 435-443.e4
        • Chen K.W.
        • Focke-Tejkl M.
        • Blatt K.
        • Kneidinger M.
        • Gieras A.
        • Dall'Antonia F.
        • et al.
        Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients.
        Allergy. 2012; 67: 609-621
        • Botturi K.
        • Langelot M.
        • Lair D.
        • Pipet A.
        • Pain M.
        • Chesne J.
        • et al.
        Preventing asthma exacerbations: what are the targets?.
        Pharmacol Ther. 2011; 131: 114-129
        • Linhart B.
        • Narayanan M.
        • Focke-Tejkl M.
        • Wrba F.
        • Vrtala S.
        • Valenta R.
        Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy.
        Clin Exp Allergy. 2014; 44: 278-287
        • Heymann P.W.
        • Chapman M.D.
        • Aalberse R.C.
        • Fox J.W.
        • Platts-Mills T.A.
        Antigenic and structural analysis of group II allergens (Der f II and Der p II) from house dust mites (Dermatophagoides spp).
        J Allergy Clin Immunol. 1989; 83: 1055-1067
        • Braza F.
        • Chesne J.
        • Castagnet S.
        • Magnan A.
        • Brouard S.
        Regulatory functions of B cells in allergic diseases.
        Allergy. 2014; 69: 1454-1463
        • Akdis M.
        • Akdis C.A.
        Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens.
        J Allergy Clin Immunol. 2014; 133: 621-631
        • van de Veen W.
        • Stanic B.
        • Yaman G.
        • Wawrzyniak M.
        • Sollner S.
        • Akdis D.G.
        • et al.
        IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.
        J Allergy Clin Immunol. 2013; 131: 1204-1212
        • Chesné J.
        • Braza F.
        • Mahay G.
        • Brouard S.
        • Aronica M.
        • Magnan A.
        IL-17 in severe asthma: where do we stand?.
        Am J Respir Crit Care Med. 2014; 190: 1094-1101

      Reference

        • Chen K.W.
        • Fuchs G.
        • Sonneck K.
        • Gieras A.
        • Swoboda I.
        • Douladiris N.
        • et al.
        Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering.
        Mol Immunol. 2008; 45: 2486-2498